Hepatectomy is one of the best treatments for malignant or benign lesions of the liver. The
mortality and morbidity rates after hepatectomy have declined in recent years because of the
precise measurement of liver functional reserve, a better understanding of liver anatomy,
meticulous haemostasis during operation and improved postoperative management. Although
surgical techniques have improved, life-threatening complications, such as intra-abdominal
bleeding, bile leakage and subphrenic infection, now cannot be completed avoided. The local
complications were most associated with the liver section treatment during the operation.
Hence, the need for safer and more effective hemostatic treatment than the conventional
approaches, such as intraoperative pressure by surgical gauze, ligatures, and
electrocoagulation by mono- or bipolar instruments.
Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the
controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood,
it swells into a brownish or black gelatinous mass which aids in the formation of a clot,
thereby serving as a haemostatic adjunct in the control of local haemorrhage barriers on
The present randomized clinical trial was designed to evaluate the efficacy and safety of
Surgicel® absorbable Haemostat covering the raw cut surface during the hepatectomy.